Agenus Inc. Reports 40% Revenue Growth and $39.2 Million Net Income in Q1 2026

Agenus Inc. reported significant financial developments in its latest 10-Q filing for the first quarter of 2026, showcasing a total revenue of $33.7 million, a 40% increase from $24.1 million in the same period last year. This growth was primarily driven by the recognition of $4.6 million in pre-commercial product revenue from its botensilimab and balstilimab (BOT/BAL) therapies, which are being provided to patients through regulatory-authorized access pathways. Additionally, non-cash royalty revenue related to the sale of future royalties rose to $29.1 million, up from $23.6 million in the prior year, reflecting increased sales of GlaxoSmithKline’s vaccines containing Agenus’ STIMULON QS-21 adjuvant.

The company also reported a net income of $39.2 million for the quarter, a substantial turnaround from a net loss of $26.4 million in the first quarter of 2025. This improvement was bolstered by a $40.4 million gain from the sale of its manufacturing assets to Zydus Lifesciences, which closed in January 2026. Operating expenses decreased significantly to $18.7 million from $37.4 million year-over-year, largely due to reduced research and development costs following the strategic realignment and sale of manufacturing operations.

In terms of operational metrics, Agenus has made strides in its clinical programs, including the commencement of patient enrollment in the global Phase 3 BATTMAN trial, which evaluates the efficacy of BOT/BAL in treating metastatic colorectal cancer. The company has also strengthened its liquidity position, ending the quarter with $35.0 million in cash and cash equivalents, a notable increase from $3.0 million at the end of 2025. This cash balance does not include $7.5 million held in escrow related to the Zydus agreements, which is expected to be released under specific conditions.

Agenus has also been active in pursuing strategic partnerships and financing options. The company is currently engaged in discussions for additional capital transactions and has implemented cost management measures to preserve liquidity. Despite the positive financial results, the company acknowledges the ongoing need for further capital to support its commercialization strategy for BOT/BAL and to achieve profitability. The management has expressed confidence that existing cash resources, along with anticipated revenues from early access programs, will be sufficient to meet liquidity requirements into 2027.

Looking ahead, Agenus plans to seek Accelerated Approval in the U.S. and Conditional Approval in the EU for its BOT/BAL therapies, contingent on the outcomes of ongoing clinical trials. The company remains focused on advancing its immuno-oncology pipeline while navigating the complexities of regulatory approvals and market conditions.